Related Experiment Video
Updated: Apr 28, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve implantation
Fabio C Monticelli1, Sebastian N Kunz, Thomas Keller
1Institute of Forensic Medicine, Salzburg University, Salzburg, Austria.
Abstract:
Transcatheter aortic valve implantation via transarterial or transapical access is an alternative therapy to treat high-risk patients with severe symptomatic aortic stenosis. Despite growing experience, procedural complications may still occur. We herein report an 86-year-old female patient with fatal left ventricular rupture after transapical transcatheter aortic valve implantation with an Edwards Sapien prosthesis due to severe cardiac amyloidosis.
More Related Videos
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
06:04Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care